Acute Myeloid Leukemia (AML) is a hematological malignancy of bone marrow (BM) origin characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells. Worldwide the incidence of AML has been steadily increasing over the last three decades. AML remains a therapeutic challenge due to its high heterogeneity, with various subclones possessing distinct genetic and epigenetic alterations contributing to tumor functional differences such as drug resistance. We have developed a unique class of ultrashort self-assembling peptide hydrogels and proven in previous studies the potential use of these biomaterials as a 3D culture system for various cell types. This study aims to develop a 3D AML "organoid" model using advanced self-assembling peptides and patient-derived cellular components: primarily, establishing a model that closely recapitulates the tumor microenvironment and can be used in drug screening applications to enable personalized medicine therapeutics; ultimately, providing a platform that can help in answering unresolved questions regarding tumor development and niche organization.